Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu
This article was originally published in The Pink Sheet Daily
Executive Summary
Though policy would allow the government to ignore originator patents in an emergency, "Our basic stance remains unchanged for now," KFDA says; drug maker and ingredient supplier are standing by.